Waiver from ASX Listing Rule 7.1 MINNEAPOLIS, United States and BRISBANE, Australia 7 August 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) announces that ASX has granted the C

Waiver from ASX Listing Rule 7.1

MINNEAPOLIS, United States and

BRISBANE, Australia 7 August 2025: Anteris Technologies Global Corp. (Anteris or

the Company) (NASDAQ: AVR, ASX: AVR) announces that ASX has granted the Company a waiver from ASX Listing Rule 7.1 on an ongoing basis to permit the Company to issue

new securities without obtaining security holder approval under ASX Listing Rule 7.1 (ASX Waiver).

ASX Listing Rule 7.1 restricts listed entities from issuing securities in excess of 15% of their issued share capital without security holder approval over a 12-month period

unless an exception applies.

The Company sought the ASX Waiver to provide the Company with additional flexibility when evaluating financing options and capital raising transactions, consistent with United

States public companies that are not subject to the ASX Listing Rules and are generally able to offer and sell their securities without restrictions comparable to the 15% limitation applicable under ASX Listing Rule 7.1. The Board considers the

granting of the ASX Waiver is in the best interests of the Company and its stockholders.

The ASX Waiver is subject to the following terms and conditions:

Without limiting ASX's right to vary or revoke its decision pursuant to ASX Listing Rule 18.3, ASX reserves the right to revoke the ASX Waiver if:

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical

devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to

structural heart disease patients.

Anteris' lead product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac

surgeons to treat aortic stenosis - a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance

of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT tissue, Anteris' patented anti-calcification tissue technology. ADAPT

tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and

the balloon-expandable ComASUR Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information: